In the final episode of Season 3 we journey to Atlanta, Georgia for the 2017 American Society of Hematology (ASH) annual meeting to learn more about the latest developments in hematologic malignancies, including leukemias, lymphomas and multiple myeloma.

Contrary to popular perception, it isn’t always warm and sunny in the southern states – Brrrr!:

For this episode, we interviewed an eclectic line-up of experts, some of whom abandoned the rose tinted glasses to take a more honest and realistic approach to oncology R&D:

This episode features interviews with two Titans in the field of adoptive cell therapy: Dr Carl June from the University of Pennsylvania (UPenn) and Dr Steven Rosenberg from the National Cancer Institute (NCI).

Adoptive cellular therapy is where you take T lymphocytes – T cells, “the immune warriors in the body” as you’ll Dr Rosenberg describe them, out of a patient, manipulate them in some way in the laboratory, then expand them in terms of numbers and give them back to the patient.

Dr Carl June UPenn

Dr Carl June talks about one way of manipulating a T lymphocyte through the insertion of a Chimeric Antigen Receptor (CAR) to create a CAR modified T cell.